Results 31 to 40 of about 20,247 (196)

Brief Report: High Levels of CD47 Expression in Thymic Epithelial Tumors

JTO Clinical and Research Reports, 2023
Introduction: CD47 is a tumor antigen that inhibits phagocytosis leading to immune evasion. Anti-CD47 therapy is a promising new immunotherapy across numerous tumor types, but it has not been tested in thymic epithelial tumors (TETs): thymomas and thymic
Thomas Yang Sun, MD, MHS, Brandon Nguyen, BA, Simon B. Chen, MD, Yasodha Natkunam, MD, PhD, Sukhmani Padda, MD, Matt van de Rijn, MD, Robert West, MD, PhD, Joel W. Neal, MD, PhD, Heather Wakelee, MD, Jonathan W. Riess, MD, MS   +9 more
doaj   +1 more source

Rh-related antigen CD47 is the signal-transducer integrin-associated protein.

Journal of Biological Chemistry, 1994
Integrin-associated protein (IAP) is a 50-kDa membrane protein with an amino-terminal immunoglobulin domain and a carboxyl-terminal multiply membrane-spanning region. It is physically and functionally associated with the integrin alpha v beta 3 vitronectin receptor and is involved in the increase in intracellular calcium concentration, which occurs ...
F P, Lindberg, D M, Lublin, M J, Telen, R A, Veile, Y E, Miller, H, Donis-Keller, E J, Brown   +6 more
openaire   +2 more sources

SIRPα - CD47 axis regulates dendritic cell-T cell interactions and TCR activation during T cell priming in spleen

PLoS ONE, 2022
The SIRPα-CD47 axis plays an important role in T cell recruitment to sites of immune reaction and inflammation but its role in T cell antigen priming is incompletely understood.
Anu Autio, Huan Wang, Francisco Velázquez, Gail Newton, Charles A. Parkos, Pablo Engel, Daniel Engelbertsen, Andrew H. Lichtman, Francis W. Luscinskas   +8 more
doaj   +2 more sources

Mitigating of the interference of anti-CD47 monoclonal antibody on transfusion compatibility detection

Zhongguo shuxue zazhi, 2023
Objective To evaluate the interference of anti-CD47 monoclonal antibody on transfusion compatibility detection, in order to establish methods for removing interference and evaluate its efficacy. Methods Blood samples from 8 patients in our clinical trial
Yiyang LYU, Wenbing KONG, Xiaogang CHEN, Chixiang LIU, Piao LYU, Hui ZHAO, Xue LIN, Huayou ZHOU   +7 more
doaj   +1 more source

A Novel Affinity Engineered Anti-CD47 Antibody With Improved Therapeutic Index That Preserves Erythrocytes and Normal Immune Cells

Frontiers in Oncology, 2022
Therapeutic blockade of the CD47/SIRPα axis by small molecules or monoclonal antibodies (mAbs) is a proven strategy to enhance macrophages-mediated anti-tumor activity.
Youg R. Thaker, Ianne Rivera, Ianne Rivera, Christophe Pedros, Christophe Pedros, Alok R. Singh, Laura Rivero-Nava, Heyue Zhou, Barbara A. Swanson, Barbara A. Swanson, Lisa Kerwin, Yanliang Zhang, J. Dixon Gray, Gunnar F. Kaufmann, Gunnar F. Kaufmann, Henry Ji, Robert D. Allen, Damien Bresson   +17 more
doaj   +1 more source

Nanomaterial Strategies for Pulmonary Delivery of Immunotherapeutics in Lung Cancer Treatment

Advanced Healthcare Materials, EarlyView.
Inhalable immunotherapeutic nanomedicines enable organ‐selective immune modulation by overcoming pulmonary delivery barriers and concentrating therapy within lung tumors. This Review defines how nanomaterial properties govern airway deposition, retention, cellular partitioning, and immune activation across vaccines, checkpoint blockade, STING agonists,
Han Zhang, Wei Tang
wiley   +1 more source

Genome‐Wide CRISPR Screen Identifies a microRNA Orchestrating Pleiotropic Resistance to Targeted Therapy and T Cell Immunity in Melanoma

Advanced Science, EarlyView.
A genome‐wide microRNA CRISPR screen identifies miR‐18a as a master regulator of cross‐resistance in melanoma. Loss of miR‐18a activates the AJUBA–YAP/Hippo axis to confer BRAFi resistance and enhances THBS1–CD47 interaction to impair CD8+ T cell immunity. hnRNP A1 is identified as an upstream regulator of miR‐18a processing.
Zhao Wang, Haotian Liu, Xueqi Wang, Jianjin Teng, Zihan Zheng, Jingya Zhang, Wanyi Xiao, Qian Liang, Jiaxin Li, Xiaomeng Jia, Xin Feng, Hongzhang Cui, Menghan Luo, Tielong Yang, Liuxing Wu, Ke Zhao, Weilong Yang, Mulin Jun Li, Dandan Huang, Jilong Yang   +19 more
wiley   +1 more source

Mitigating Cancer Therapy–Related Cognitive Impairment by Targeted Activation of Undruggable Phosphatase

Advanced Science, EarlyView.
An RVG‑engineered exosomal saRNA delivery system (RVG‑EVs‑saPtpro) effectively targets and activates hippocampal PTPRO, functioning as a “molecular brake” to alleviate cancer therapy‑related cognitive impairment (CTRCI) by enhancing neuronal survival, neurogenesis, and synaptic plasticity.
Zhimeng Yao, Yuhua Meng, Huanyi Li, Yinhui Jiang, Xiaona Lin, Mengyuan Hu, Qing Liu, Xiaofu Qiu, Hongzheng Ren, Yunlong Pan, Bin Pan, Zexiong Guo, Shuyao Zhang, Dianzheng Zhang, Li Yang, Shegan Gao, Weijing Deng, Jianfan Chen, Hao Zhang   +18 more
wiley   +1 more source

Engineering Approaches to Modify Immunomodulatory Functions of Mesenchymal Stromal Cells (MSCs): Tissue Regeneration and Clinical Application

Advanced Science, EarlyView.
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang, Kejia Li, Ning Wang, Zhen Li, Zhiyong Zhang, Rocky S. Tuan, Yangzi Jiang   +6 more
wiley   +1 more source

Research Progress of CD47-SIRPα Signaling Axis as An Innate Immune Checkpoint in Cancer

Zhongliu Fangzhi Yanjiu, 2018
Immune checkpoint inhibitors, including those targeting CTLA-4/B7 and PD-1/PD-L1 inhibitory pathways, are now available for clinical use on cancer patients. Other interesting checkpoint inhibitors are currently under the development.
ZHA Li, YU Jiaojiao, XU Bin
doaj   +1 more source